Publications

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Atherosclerosis 2016 Jun 26;249:36-43. Epub 2016 Feb 26.
Laboratory for Systems Biology and Medicine (LSBM), Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8904, Japan. Electronic address:




Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis.
Arterioscler Thromb Vasc Biol 2009 Apr 5;29(4):548-54. Epub 2009 Feb 5.
Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada.

Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages.
Arterioscler Thromb Vasc Biol 2008 Dec 18;28(12):2288-95. Epub 2008 Sep 18.
Institut Pasteur de Lille, Inserm, U545, Université de Lille 2, Faculté de Pharmacie et de Médecine Lille, Lille, France.



The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages.
Mol Endocrinol 2008 Aug 29;22(8):1797-811. Epub 2008 May 29.
Institut National de la Santé et de la Recherche Médicale, Unité 545, Institut Pasteur de Lille, 1, rue du Professeur Calmette, Boite Postale 245, Lille 59019, France.


Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
Bioorg Med Chem Lett 2007 Aug 24;17(16):4689-93. Epub 2007 May 24.
Tokyo New Drug Research Laboratories 1, Pharmaceutical Division, Kowa Co., LTD, 2-17-43, Noguchicho, Higashimurayam, Tokyo 189-0022, Japan.

The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
J Cardiovasc Pharmacol 2007 Jun;49(6):408-15
Department of Experimental Pharmacology EA 1046, University Hospital of Cardiology, Faculty of Medicine, University of Lille 2, Lille, France.







Plasma cystatin-C and development of coronary heart disease: The PRIME Study.
Atherosclerosis 2006 Apr 25;185(2):375-80. Epub 2005 Jul 25.
Department of Atherosclerosis, SERLIA-INSERM UR545, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille Cedex, France and University Lille II, France.







PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Arterioscler Thromb Vasc Biol 2005 Sep 30;25(9):1897-902. Epub 2005 Jun 30.
INSERM U545, Département d'Athérosclerose, Institut Pasteur de Lille, 1 rue du Professeur Calmette, 59019 Lille cédex, France.


The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition.
J Biol Chem 2005 Aug 16;280(33):29971-9. Epub 2005 May 16.
U.R. 545 INSERM, Atherosclerosis Department, Pasteur Institute of Lille and the Faculty of Pharmacy, Lille2 University, France.


Complete functional rescue of the ABCA1-/- mouse by human BAC transgenesis.
J Lipid Res 2005 Jun 16;46(6):1113-23. Epub 2005 Mar 16.
Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V5Z 4H4, Canada.

Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha.
Arterioscler Thromb Vasc Biol 2005 Jun 24;25(6):1186-92. Epub 2005 Mar 24.
Département d'Athérosclérose, U.545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, Lille Cedex, France.




The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c.
J Biol Chem 2004 Oct 17;279(44):45462-9. Epub 2004 Aug 17.
Département d'Athérosclérose, UR545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie de Lille, 1 rue du Pr. Calmette BP 245, 59019 Lille Cedex, France, Genfit SA, Loos F-59120, France.

The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha.
Mol Endocrinol 2004 Aug 6;18(8):1906-18. Epub 2004 May 6.
UR 545 Institut National de la Santé et de la Recherche Médicale, Département d'Athérosclérose, Institut Pasteur de Lille, 1 rue du Pr. Calmette, 59019 Lille, France.

Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release.
Biochim Biophys Acta 2004 Jul;1683(1-3):69-77
Department of Research on Atherosclerosis, Inserm UMR545, Institut Pasteur de Lille et Faculté des Sciences Pharmaceutiques et Biologiques, Université de Lille 2, 3 rue du Professeur Laguesse, BP 83 59006 Lille Cedex, France.

Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.
Biochem Biophys Res Commun 2004 Jun;319(2):397-404
Département d'Athérosclérose, UR 545 INSERM, Institut Pasteur de Lille et Université de Lille II, 1 rue du Pr. Calmette-BP 245, 59019 Lille Cedex, France.

Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
Arch Med Res 2004 May-Jun;35(3):235-40
Laboratorio de Lípidos y Lipoproteínas, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.


OF